Drug Name: Verdeso (desonide) Company: Connetics Corporation Approval Status: Approved September 2006 Treatment Area: atopic dermatitis

Dermatitis introduction: There are several different types of dermatitis. The different kinds usually have in common an allergic reaction to specific allergens. The term may describe eczema, which is also called dermatitis eczema and eczematous dermatitis. An eczema diagnosis often implies atopic dermatitis (childhood eczema) but, without proper context, means nothing more than "a rash".[

symptoms of atopic dermatitis vary from person to person, the most common symptoms are dry, itchy, red skin. Typical affected skin areas include the folds of the arms, the back of the knees, wrists, face and hands. Less commonly there may be cracks behind the ears, and various other rashes on any part of the body. Itching is the primary symptoms of this condition.

. Verdeso : Verdeso (desonide) Foam is a petrolatum-based emulsion aerosol foam containing the active ingredient desonide, a low-potency topical corticosteroid. Desonide is a white powder or crystal that is practically insoluble in water, sparingly soluble in ethanol and in acetone, and soluble in chloroform.

Mechanism of Action: Verdeso Foam is a topical corticosteroid which are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. These proteins are believed to control the biosynthesis of potent mediators of inflammation, such as prostaglandins and leukotrienes, by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.

Pharmacokinetics : Verdeso is specifically indicated for the treatment of mild to moderate atopic dermatitis in patients 3 months of age and older. It gives twice a day as a thin layer of small amount from the foam .

Side Effects: Upper respiratory tract infection Cough Application site burning Application site reaction Viral infection Headache Irritability Asthma

Cautions and contraindications : In addition, in a clinical study Verdeso was shown to cause adrenal suppression in 4% of the pediatric subjects after 4 weeks of use. Systemic absorption of topical corticosteroids has produced reversible HPA axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients. Verdeso Foam is contraindicated in subjects who are hypersensitive to desonide or to any ingredient in this preparation. Treatment should not exceed four consecutive weeks.

Thanks for your attention Done by Dania awad